title: Two etomidate sites in α1β2γ2 γ-aminobutyric acid type A receptors contribute equally and noncooperatively to modulation of channel gating.
abstract: BACKGROUND
  Etomidate is a potent hypnotic agent that acts via γ-aminobutyric acid receptor type A (GABA(A)) receptors. Evidence supports the presence of two etomidate sites per GABA(A) receptor, and current models assume that each site contributes equally and noncooperatively to drug effects. These assumptions remain untested.
  
  
  METHODS
  We used concatenated dimer (β2-α1) and trimer (γ2-β2-α1) GABA(A) subunit assemblies that form functional α1β2γ2 channels, and inserted α1M236W etomidate site mutations into both dimers (β2-α1M236W) and trimers (γ2-β2-α1M236W). Wild-type or mutant dimers (D(wt) or D(αM236W)) and trimers (T(wt) or T(αM236W)) were coexpressed in Xenopus oocytes to produce four types of channels: D(wt)T(wt), D(αM236W)T(wt), D(wt)T(αM236W), and D(αM236W)T(αM236W). For each channel type, two-electrode voltage clamp was performed to quantitatively assess GABA EC(50), etomidate modulation (left shift), etomidate direct activation, and other functional parameters affected by αM236W mutations.
  
  
  RESULTS
  Concatenated wild-type D(wt)T(wt) channels displayed etomidate modulation and direct activation similar to α1β2γ2 receptors formed with free subunits. D(αM236W)T(αM236W) receptors also displayed altered GABA sensitivity and etomidate modulation similar to mutated channels formed with free subunits. Both single-site mutant receptors (D(αM236W)T(wt) and D(wt)T(αM236W)) displayed indistinguishable functional properties and equal gating energy changes for GABA activation (-4.9 ± 0.48 vs. -4.7 ± 0.48 kJ/mol, respectively) and etomidate modulation (-3.4 ± 0.49 vs. -3.7 ± 0.38 kJ/mol, respectively), which together accounted for the differences between D(wt)T(wt) and D(αM236W)T(αM236W) channels.
  
  
  CONCLUSIONS
  These results support the hypothesis that the two etomidate sites on α1β2γ2 GABA(A) receptors contribute equally and noncooperatively to drug interactions and gating effects.
authors.affiliation: Department of Neurobiology, Boston University, Boston, MA, USA.
authors.forename: Grigori
authors.initials: G
authors.lastname: Guitchounts
authors.forename: Deirdre S
authors.initials: DS
authors.lastname: Stewart
authors.forename: Stuart A
authors.initials: SA
authors.lastname: Forman
mesh_terms: D000595:Amino Acid Sequence; D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D000818:Animals; D005045:Etomidate / Q000494:pharmacology*; D005260:Female; D018755:GABA Agonists / Q000494:pharmacology; D015640:Ion Channel Gating / Q000187:drug effects*; D008969:Molecular Sequence Data; D009154:Mutation; D009865:Oocytes / Q000187:drug effects; D018408:Patch-Clamp Techniques; D010957:Plasmids / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D011963:Receptors, GABA-A / Q000187:drug effects* / Q000235:genetics; D014982:Xenopus laevis; D005680:gamma-Aminobutyric Acid / Q000502:physiology
chemical_list: D018686:Anesthetics, Intravenous; D018755:GABA Agonists; D012333:RNA, Messenger; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; D005045:Etomidate